Search

Stewart Washer

A 2006 40under40 winner, Dr Stewart Washer has 20 years of CEO and board experience, founding several biotechnology companies in both the agri-food and medical sectors. He is currently the chairman of Orthocell Ltd, which cultures tendon cells to repair damaged tendons, chairman of Cynata Therapeutics Ltd (ASX:CYP) which is developing stem cell therapies and chairman of Minomic International Ltd which have an accurate non-invasive test for prostate cancer. He was previously the CEO of Calzada Ltd (ASX:CZD), the founding CEO of Phylogica Ltd (ASX:PYC) and before this, he was CEO of Celentis and managed the commercialisation of intellectual property from AgResearch in New Zealand with 650 Scientists and $130m revenues. He was also a founder of a NZ$120m New Zealand based life science fund and Venture Partner with the Swiss based Inventages Nestlé Fund. He is currently investment director with Bioscience Managers. Stewart has held a number of Board positions in the past as the chairman of iSonea Ltd (ASX:ISN), Resonance Health Ltd (ASX:RHT) and Hatchtech Pty Ltd, a director of iCeutica Pty Ltd, Immuron Ltd (ASX:IMC) and AusBiotech Ltd. He was also a senator with Murdoch University and is currently the chairman of Firefly Health. In March 2005, Dr Washer took biotechnology company Phylogica through a successful and oversubscribed initial public offering to list on the ASX at a 30 per cent premium. Phylogica had a novel drug discovery technology based on parts of proteins derived from diverse micro-organisms that are being developed to treat stroke, diabetes, asthma and other inflammatory diseases.
Bio last updated 21 Jul 2018

Article Timeline

Access to our data for Stewart Washer is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

Stewart Washer is linked to 8 organisations which are included in 2 lists - Public Companies - Industrial and Business News 30.

To see the data you will need to .

Total Shareholder Return as at 29/06/18

1 year TSR5 year TSR
465thJV Global0%-11%
547thOrthocell-11%0%
655thCoAssets-30%0%
693rdStructural Monitoring Systems-40%111%
762nd333D-59%-34%
722 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Roles

2016
Founder, Non-Executive Director (since July 2018); (Executive Director 2016-2018)
2014
Executive Chairman
2013
Executive Chair
Year started and most recent title

Share Transactions

21/03/18
$0 Other
21/03/18
$0 Bought
30/06/17
$0 Bought
Total value as at the date of the transaction
Source: Morningstar

Revenue

148th↓Orthocell$1.0m
163rd↓JV Global$487k
164th↑333D$342k
166th↓CoAssets$322k
167th↓Structural Monitoring Systems$312k
239 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer